RESUMEN
BACKGROUND: Northwell Health, an integrated health system in New York, has treated more than 15,000 inpatients with COVID-19 at the US epicenter of the SARS-CoV-2 pandemic. OBJECTIVE: We describe the demographic characteristics of patients who died of COVID-19, observation of frequent rapid response team/cardiac arrest (RRT/CA) calls for non-intensive care unit (ICU) patients, and factors that contributed to RRT/CA calls. METHODS: A team of registered nurses reviewed the medical records of inpatients who tested positive for SARS-CoV-2 via polymerase chain reaction before or on admission and who died between March 13 (first Northwell Health inpatient expiration) and April 30, 2020, at 15 Northwell Health hospitals. The findings for these patients were abstracted into a database and statistically analyzed. RESULTS: Of 2634 patients who died of COVID-19, 1478 (56.1%) had oxygen saturation levels ≥90% on presentation and required no respiratory support. At least one RRT/CA was called on 1112/2634 patients (42.2%) at a non-ICU level of care. Before the RRT/CA call, the most recent oxygen saturation levels for 852/1112 (76.6%) of these non-ICU patients were at least 90%. At the time the RRT/CA was called, 479/1112 patients (43.1%) had an oxygen saturation of <80%. CONCLUSIONS: This study represents one of the largest reviewed cohorts of mortality that also captures data in nonstructured fields. Approximately 50% of deaths occurred at a non-ICU level of care despite admission to the appropriate care setting with normal staffing. The data imply a sudden, unexpected deterioration in respiratory status requiring RRT/CA in a large number of non-ICU patients. Patients admitted at a non-ICU level of care suffered rapid clinical deterioration, often with a sudden decrease in oxygen saturation. These patients could benefit from additional monitoring (eg, continuous central oxygenation saturation), although this approach warrants further study.
Asunto(s)
Infecciones por Coronavirus/mortalidad , Demografía , Neumonía Viral/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Betacoronavirus , COVID-19 , Estudios de Cohortes , Femenino , Paro Cardíaco/epidemiología , Paro Cardíaco/mortalidad , Mortalidad Hospitalaria , Equipo Hospitalario de Respuesta Rápida , Hospitalización/estadística & datos numéricos , Humanos , Pacientes Internos/estadística & datos numéricos , Unidades de Cuidados Intensivos , Masculino , Registros Médicos , Persona de Mediana Edad , New York/epidemiología , Oxígeno/metabolismo , Pandemias , SARS-CoV-2 , Adulto JovenRESUMEN
BACKGROUND: A low (0-3) History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score reliably identifies ED chest pain patients who are low risk for near-term major adverse cardiac events (MACE). To optimize sensitivity, many clinicians employ a modified HEART score by repeating troponin measurements and excluding patients with abnormal troponin values or ischemic electrocardiograms (ECGs). The residual MACE risk among patients with otherwise non-low (≥4) modified HEART scores is thus likely much lower than with non-low original HEART scores. OBJECTIVE: To explore residual 60-day MACE risks among patients with non-low modified HEART scores. METHODS: Secondary analysis of a retrospective cohort of ED patients presenting with chest pain to an integrated healthcare system between 2013 and 2015. Patients with serial troponin measurements within 6 h of ED arrival were considered for inclusion. Exclusions included an ischemic ECG, troponin values above the 99th percentile or a lack of continuous health plan coverage through the 60-day follow-up period. MACE was defined as a composite of myocardial infarction, cardiac arrest, cardiogenic shock or death. RESULTS: There were 22,976 study eligible patients encounters, 13,521 (59%) of which had non-low (≥4) modified HEART scores. The observed 60-day MACE risk among non-low HEART score patients was 2.0% (95% CI 1.8-2.3). When including all coronary revascularizations (MACE-R), the risk was 4.4% (95% CI 4.1-4.4). CONCLUSION: Risk of near-term MACE among patients with non-low modified HEART scores (excluding those with abnormal troponin or ischemic ECGs) appears to be much lower than in the original HEART score validation studies.
Asunto(s)
Síndrome Coronario Agudo/diagnóstico , Dolor en el Pecho/diagnóstico , Paro Cardíaco/epidemiología , Infarto del Miocardio/epidemiología , Choque Cardiogénico/epidemiología , Síndrome Coronario Agudo/sangre , Síndrome Coronario Agudo/complicaciones , Síndrome Coronario Agudo/fisiopatología , Factores de Edad , Dolor en el Pecho/sangre , Dolor en el Pecho/etiología , Dolor en el Pecho/fisiopatología , Electrocardiografía , Servicio de Urgencia en Hospital , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mortalidad , Revascularización Miocárdica/estadística & datos numéricos , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Troponina I/sangreRESUMEN
BACKGROUND: Women experience less appropriate implantable cardioverter-defibrillator (ICD) interventions and are underrepresented in randomised ICD trials. Sex-differences in inducible and spontaneous ventricular tachycardia/fibrillation (VT/VF), cardiac arrest and sudden cardiac death (SCD) early post-myocardial infarction (MI) require further study. METHODS: Consecutive ST-elevation MI patients with left ventricular ejection fraction (LVEF)≤40% underwent electrophysiology study (EPS) to target early prevention of SCD. An ICD was implanted for a positive (inducible monomorphic VT) but not a negative (no arrhythmia or inducible VF) EPS. The combined primary endpoint of VT/VF (spontaneous or ICD-treated), cardiac arrest or SCD was assessed using competing risk survival analysis in women versus men with adjustment for confounders. Logistic regression was used to determine independent predictors of inducible VT at EPS. RESULTS: A total of 403 patients (16.9% female) underwent EPS. Women were significantly older than men but with similar LVEF (31.5 ± 6.3 versus 31.6 ± 6.4%, p = 0.91). Electrophysiology study was positive for inducible VT in 22.1% and 33.4% (p = 0.066) and an ICD implanted in 25.0% and 33.4% (p = 0.356) of women versus men. Appropriate ICD activations (VT/VF) occurred in 5.9% of women and 36.6% of men (p = 0.012). The adjusted cumulative primary endpoint incidence was significantly lower in women than men (1.6% versus 26.5%, p = 0.03). Female sex was not an independent predictor of inducible VT at EPS (HR 0.63, 95% CI 0.33-1.23, p = 0.178). CONCLUSIONS: Women with early post-MI cardiomyopathy had lower VT/VF, cardiac arrest and SCD, compared to men. In ICD recipients the rate of appropriate activations was six-fold less in women compared to men.
Asunto(s)
Muerte Súbita Cardíaca/epidemiología , Técnicas Electrofisiológicas Cardíacas , Infarto del Miocardio con Elevación del ST/complicaciones , Taquicardia Ventricular/epidemiología , Australia/epidemiología , Muerte Súbita Cardíaca/etiología , Femenino , Estudios de Seguimiento , Paro Cardíaco/epidemiología , Paro Cardíaco/etiología , Paro Cardíaco/fisiopatología , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Infarto del Miocardio con Elevación del ST/fisiopatología , Factores Sexuales , Tasa de Supervivencia/tendencias , Taquicardia Ventricular/etiología , Taquicardia Ventricular/fisiopatologíaRESUMEN
Introduction : L'Arrêt Cardio-Respiratoire (ACR) est un évènement fréquent dans les services d'urgences et de réanimation pédiatrique. Bien que de nombreuses données soient rapportées dans plusieurs régions du monde, peu sont disponibles en Afrique subsaharienne. L'objectif de cette étude était d'évaluer les aspects épidémiologiques, thérapeutiques et le pronostic des enfants victimes d'ACR au CNHEAR.Patients et méthodes : Il s'agissait d'une étude prospective sur 1 an, concernant les enfants âgés de 0 à 15 ans, ayant présenté un ACR et bénéficié de manÅuvres de réanimation au CNHEAR. Les données ont été saisies et analysées avec le logiciel Epi info 3.5.4 et SPSS 24.0. Résultats : Cent-soixante-dix-neuf (179) cas d'ACR ont été enregistrés. Les motifs de consultation les plus fréquents étaient la fièvre et la détresse respiratoire (38,5% chacun). Le délai de consultation moyen était de 3,5 jours. Quarante-neuf virgule sept pour cent (49,7%) avaient consulté dans une structure périphérique avant d'atteindre le niveau central et 13,9% étaient transportés par un transport médicalisé. Les principales circonstances ayant conduit à l'ACR étaient la détresse respiratoire (45,2%), la défaillance hémodynamique (48,7%), et les troubles métaboliques (19,6%). Les pathologies sous- jacentes étaient dominées par le sepsis 20,1%. Au plan thérapeutique, 71,5% avaient eu un massage cardiaque externe. Au décours de la réanimation initiale, le retour à une activité cardio-circulatoire spontanée était de 60,9%. L'évolution secondaire était marquée par la récidive de l'ACR chez 71,6% et finalement le décès de 85,3%. Au final, sur les 179 enfants ayant fait un ACR et bénéficié d'une réanimation, 16 (8,9%) ont survécu et ont été suivis en ambulatoire.Conclusion : La survie après ACR pédiatrique au Sénégal est faible. Des efforts importants restent à faire, notamment une amélioration des ressources matérielles ainsi que des compétences et la formation continue des praticiens en vue d'une meilleure prise en charge des enfants gravement malades
Asunto(s)
Niño , Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Senegal , Resultado del TratamientoRESUMEN
BACKGROUND AND PURPOSE: Rheumatic valvular heart disease is associated with the increased risk of cerebrovascular events, although there are limited data on the prognosis of patients with rheumatic mitral valve disease (RMVD) after stroke. METHODS: We examined the association between RMVD and both serious and common cardiovascular and noncardiovascular (respiratory and infective) complications in a cohort of hospitalized stroke patients based in Thailand. Factors associated with in-hospital mortality were also explored. Data were obtained from a National Insurance Database. All hospitalized strokes between October 1, 2004, and January 31, 2013, were included in the current study. Characteristics and outcomes were compared for RMVD and non-RMVD patients. Logistic regression, propensity score matching, and multivariate models were used to assess study outcomes. RESULTS: In total, 594 681 patients (mean [SD] age=64 [14.5] years) with a diagnosis of stroke (ischemic=306 154; hemorrhagic=195 392; undetermined=93 135) were included in this study, of whom 5461 had RMVD. Results from primary analyses showed that after ischemic stroke, and controlling for potential confounding covariates, RMVD was associated (P<0.001) with increased odds for cardiac arrest (odds ratio [95% confidence interval]=2.13 [1.68-2.70]), shock (2.13 [1.64-2.77]), arrhythmias (1.70 [1.21-2.39]), respiratory failure (2.09 [1.87-2.33]), pneumonia (2.00 [1.81-2.20]), and sepsis (1.39 [1.19-1.63]). In hemorrhagic stroke patients, RMVD was associated with increased odds (fully adjusted model) for respiratory failure (1.26 [1.01-1.57]), and in patients with undetermined stroke, RMVD was associated with increased odds (fully adjusted analyses) for shock (3.00 [1.46-6.14]), respiratory failure (2.70 [1.91-3.79]), and pneumonia (2.42 [1.88-3.11]). CONCLUSIONS: RMVD is associated with the development of cardiac arrest, shock, arrhythmias, respiratory failure, pneumonia, and sepsis after acute stroke.
Asunto(s)
Isquemia Encefálica/epidemiología , Hemorragia Cerebral/epidemiología , Insuficiencia de la Válvula Mitral/epidemiología , Estenosis de la Válvula Mitral/epidemiología , Evaluación de Resultado en la Atención de Salud/estadística & datos numéricos , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Arritmias Cardíacas/epidemiología , Arritmias Cardíacas/etiología , Isquemia Encefálica/complicaciones , Hemorragia Cerebral/complicaciones , Bases de Datos Factuales/estadística & datos numéricos , Femenino , Paro Cardíaco/epidemiología , Paro Cardíaco/etiología , Humanos , Masculino , Persona de Mediana Edad , Programas Nacionales de Salud/estadística & datos numéricos , Neumonía/epidemiología , Neumonía/etiología , Insuficiencia Respiratoria/epidemiología , Insuficiencia Respiratoria/etiología , Cardiopatía Reumática , Sepsis/epidemiología , Sepsis/etiología , Choque/epidemiología , Choque/etiología , Accidente Cerebrovascular/etiología , Tailandia/epidemiologíaAsunto(s)
Reanimación Cardiopulmonar , Cardioversión Eléctrica , Paro Cardíaco/diagnóstico , Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Prestación Integrada de Atención de Salud , Paro Cardíaco/mortalidad , Humanos , Evaluación de Procesos y Resultados en Atención de Salud , Pronóstico , Publicaciones , Investigación , Análisis de Supervivencia , Estados UnidosRESUMEN
OBJECTIVES: In Incremental Decrease in Endpoints through Aggressive Lipid-lowering (IDEAL), we compared cardiovascular outcomes in patients with and without chronic kidney disease (CKD) (estimated glomerular filtration rate <60 mL min(-1) 1.73 m(-2)) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events. DESIGN: Exploratory analysis of CV endpoints in a randomized trial comparing high dose of atorvastatin to usual dose of simvastatin on MCE. SETTINGS: Patients with CKD were compared with the non-CKD patients. Cox regression models were used to study the relationships between on-treatment levels of LC and incident MCE. FINDINGS: Chronic kidney disease was strongly associated with cardiovascular end-points including total mortality. In patients with CKD, a significant benefit of high dose atorvastatin treatment was found for any CV events, stroke and peripheral artery disease, but not for MCE. However, all cardiovascular end-points except stroke and CV mortality were reduced in the non-CKD group. Differential changes in LC or relationships to LC could not explain the different treatment outcomes in MCE in the two groups. INTERPRETATION: Chronic kidney disease was a powerful risk factor for all cardiovascular end-points. The reason why the significant reductions achieved by high-dose statin treatment in most CV end-points in the non-CKD group were only in part matched by similar reductions in the CKD patients is not apparent. This difference did not result from differential changes in or relations to LC, but limited power may have increased the possibility of chance findings.
Asunto(s)
Enfermedades Cardiovasculares/sangre , Fallo Renal Crónico/sangre , Lipoproteínas/sangre , Enfermedad Aguda , Anciano , Anticolesterolemiantes/uso terapéutico , Atorvastatina , Biomarcadores/sangre , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/mortalidad , Femenino , Tasa de Filtración Glomerular , Paro Cardíaco/epidemiología , Paro Cardíaco/prevención & control , Ácidos Heptanoicos/uso terapéutico , Humanos , Fallo Renal Crónico/complicaciones , Masculino , Persona de Mediana Edad , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/epidemiología , Infarto del Miocardio/prevención & control , Valor Predictivo de las Pruebas , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Pirroles/uso terapéutico , Análisis de Regresión , Simvastatina/uso terapéuticoRESUMEN
OBJECTIVE: To assess the survival benefit and safety profile of low-dose (850 mg/kg) and high-dose (1350 mg/kg) phospholipid emulsion vs. placebo administered as a continuous 3-day infusion in patients with confirmed or suspected Gram-negative severe sepsis. Preclinical and ex vivo studies show that lipoproteins bind and neutralize endotoxin, and experimental animal studies demonstrate protection from septic death when lipoproteins are administered. Endotoxin neutralization correlates with the amount of phospholipid in the lipoprotein particles. DESIGN: A three-arm, randomized, blinded, placebo-controlled trial. SETTING: Conducted at 235 centers worldwide between September 2004 and April 2006. PATIENTS: A total of 1379 patients participated in the study, 598 patients received low-dose phospholipid emulsion, and 599 patients received placebo. The high-dose phospholipid emulsion arm was stopped, on the recommendation of the Independent Data Monitoring Committee, due to an increase in life-threatening serious adverse events at the fourth interim analysis and included 182 patients. MEASUREMENTS AND MAIN RESULTS: A 28-day all-cause mortality and new-onset organ failure. There was no significant treatment benefit for low- or high-dose phospholipid emulsion vs. placebo for 28-day all-cause mortality, with rates of 25.8% (p = .329), 31.3% (p = .879), and 26.9%, respectively. The rate of new-onset organ failure was not statistically different among groups at 26.3%, 31.3%, 20.4% with low- and high-dose phospholipid emulsion, and placebo, respectively (one-sided p = .992, low vs. placebo; p = .999, high vs. placebo). Of the subjects treated, 45% had microbiologically confirmed Gram-negative infections. Maximal changes in mean hemoglobin levels were reached on day 10 (-1.04 g/dL) and day 5 (-1.36 g/dL) with low- and high-dose phospholipid emulsion, respectively, and on day 14 (-0.82 g/dL) with placebo. CONCLUSIONS: Treatment with phospholipid emulsion did not reduce 28-day all-cause mortality, or reduce the onset of new organ failure in patients with suspected or confirmed Gram-negative severe sepsis.
Asunto(s)
Emulsiones Grasas Intravenosas/administración & dosificación , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Fosfolípidos/administración & dosificación , Sepsis/tratamiento farmacológico , Acidosis/epidemiología , Bilirrubina/sangre , Colesterol/sangre , Trastornos del Conocimiento/epidemiología , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Emulsiones Grasas Intravenosas/efectos adversos , Femenino , Infecciones por Bacterias Gramnegativas/mortalidad , Paro Cardíaco/epidemiología , Hemoglobinas/análisis , Humanos , Fallo Hepático/epidemiología , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/epidemiología , Fosfolípidos/efectos adversos , Sepsis/microbiología , Sepsis/mortalidad , Índice de Severidad de la EnfermedadRESUMEN
People with epilepsy may have abnormal cardiac function. This has been linked to a greater incidence of sudden unexpected death in epilepsy (SUDEP). In the present review, we assess the evidence linking cardiac failure to SUDEP, and propose the use of the maximal pentylenetetrazol seizure test to model SUDEP in animals to identify causal links between cardiac failure and SUDEP. We also discuss recent claims on the use of omega-3 polyunsaturated fatty acids to reduce the incidence of SUDEP because of their cardioprotective and anticonvulsant effects.
Asunto(s)
Anticonvulsivantes , Cardiotónicos , Muerte Súbita Cardíaca/epidemiología , Epilepsia/epidemiología , Ácidos Grasos Omega-3/farmacología , Paro Cardíaco/epidemiología , Animales , Arritmias Cardíacas/etiología , Arritmias Cardíacas/fisiopatología , Convulsivantes , Humanos , Isquemia Miocárdica/epidemiología , Isquemia Miocárdica/fisiopatología , Pentilenotetrazol , Convulsiones/inducido químicamente , Convulsiones/epidemiologíaRESUMEN
The oculocardiac reflex (OCR) is a well-known phenomenon in ophthalmic surgery, but is rarely described in aesthetic blepharoplasty surgery. It was first mentioned in 1908 by Ascher and Dagnini. Since then, ophthalmologists and anaesthesiologists have regarded the onset of the oculocardiac reflex as a significant intraoperative problem, which is undermined by several case reports that describe dysrhythmias which have haved caused morbidity and death. Per definition the OCR is caused by ocular manipulation and involves intraoperative bradycardia by a change of 20 beats/minute compared to the preoperative heart rate or any dysrhythmia during the manipulation via a trigeminal-vagal-mediated reflex arc. Having operated on a 48-year-old, healthy woman in our clinic, who underwent a cardiac arrest during the blepharoplasty procedure, followed by a successful resuscitation, we investigated the onset of the OCR in our blepharoplasty patients within the last 3 years. The onset of the OCR was noted in 22 of 110 (20 %) blepharoplasty patients, mainly affecting younger, low-weighted patients operated under local anaesthesia. Awareness and treatment of this potentially life-threatening oculocardiac reflex are necessary. In most cases the onset of the reflex may be avoided by a gentle operation technique and by refraining from severe traction to the muscle or fat pad. The best treatment of a profound bradycardia caused by the OCR is to release tension to the muscle or fat pad in order to permit the heart rate to return to normal. Intraoperative monitoring is of utmost importance.
Asunto(s)
Blefaroplastia , Paro Cardíaco/fisiopatología , Complicaciones Intraoperatorias/fisiopatología , Reflejo Oculocardíaco/fisiología , Tejido Adiposo/cirugía , Anestesia Local , Presión Sanguínea/fisiología , Bradicardia/epidemiología , Bradicardia/fisiopatología , Estudios Transversales , Electrocardiografía , Femenino , Paro Cardíaco/epidemiología , Humanos , Complicaciones Intraoperatorias/epidemiología , Persona de Mediana Edad , Monitoreo Intraoperatorio , Órbita/cirugía , Resucitación , Factores de Riesgo , Nervio Trigémino/fisiopatología , Nervio Vago/fisiopatologíaRESUMEN
Hypothermia after out of hospital cardiac arrest should be clinical practice for years. But is it really meanwhile daily trained practice? A survey at northern German hospitals gives an answer to this question.
Asunto(s)
Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Hospitalización/estadística & datos numéricos , Hipertermia Inducida/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Resucitación/métodos , Resucitación/tendencias , Cuidados Críticos/estadística & datos numéricos , Alemania/epidemiología , Humanos , Guías de Práctica Clínica como Asunto , Encuestas y CuestionariosRESUMEN
CONTEXT: Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI. OBJECTIVE: To determine the effect of high-dose GIK infusion on mortality in patients with STEMI. DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted in 470 centers worldwide among 20,201 patients with STEMI who presented within 12 hours of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used. INTERVENTION: Patients were randomly assigned to receive GIK intravenous infusion for 24 hours plus usual care (n = 10,091) or to receive usual care alone (controls; n = 10,110). MAIN OUTCOME MEASURES: Mortality, cardiac arrest, cardiogenic shock, and reinfarction at 30 days after randomization. RESULTS: At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients (10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.95-1.13; P = .45). There were no significant differences in the rates of cardiac arrest (1.5% [151/10 107] in control and 1.4% [139/10,088] in GIK infusion; HR, 0.93; 95% CI, 0.74-1.17; P = .51), cardiogenic shock (6.3% [640/10 107] vs 6.6% [667/10 088]; HR, 1.05; 95% CI, 0.94-1.17; P = .38), or reinfarction (2.4% [246/10,107] vs 2.3% [236/10,088]; HR, 0.98; 95% CI, 0.82-1.17; P = .81). The rates of heart failure at 7 days after randomization were also similar between the groups (16.9% [1711/10,107] vs 17.1% [1721/10,088]; HR, 1.01; 95% CI, 0.95-1.08; P = .72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention). CONCLUSION: In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.
Asunto(s)
Soluciones Cardiopléjicas/uso terapéutico , Glucosa/uso terapéutico , Insulina/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Potasio/uso terapéutico , Anciano , Glucemia , Electrólitos/sangre , Femenino , Paro Cardíaco/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/mortalidad , Potasio/sangre , Recurrencia , Choque Cardiogénico/epidemiologíaRESUMEN
La muerte súbita cardíaca de causa eléctrica en sujetos con corazón "sano", constituye un problema clínico y de salud pública, aún no resuelto. Los objetivos del trabajo fueron: caracterizar pacientes reanimados de un evento de muerte súbita de causa eléctrica y conocer su evolución intervenida en tres años; y estudiar los signos eléctricos premonitorios de muerte súbita. Se estudiaron 42 sujetos, 30 hombres y 12 mujeres, edad promedio 37.7 años, con corazón "sano", por métodos clínicos y paraclínicos. Se consideraron 9 subpoblaciones, en mayor número los síndromes de Brugada y de QT largo y la fibrilación ventricular idiopática. Las arritmias responsables del evento fueron, en primer lugar, la fibrilación ventricular y la torsión de puntas. Existieron signos premonitorios en el 92.8% de los pacientes. Fueron frecuentes las recidivas de las arritmias malignas (71.4%) aunque en la estimulación eléctrica programada, sólo se logró reproducirlas en 4 de 18 pacientes. La fibrilación auricular predominó como arritmia coexistente (19%). En resumen, son frecuentes los signos premonitorios (en especial la fibrilación auricular) y las recidivas de las arritmias malignas aunque su inducibilidad en el laboratorio es pobre. La estratificación de riesgo es muy difícil, por el bajo valor predictivo de los métodos diagnósticos.
Sudden cardiac death due to electrical causes in individuals with no evidence of structural heart disease is an important clinical and public health problem, and it is not yet solved. The objectives of this study were: to characterize patients reanimated from a sudden death event of electrical cause; to know the mediated evolution during a period of three years and to study premonitory electrical signs. 42 individuals were studied, 30 were male and 12 female, mean age 37.7 years, healthy heart, by clinic and paraclinic methods. Nine subpopulations were studied, being Brugada syndrome, long QT syndrome and idiopathic ventricular fibrillation the most frequent. Ventricular fibrillation and twisting of the points were the arrhythmias responsible for most death events. There were premonitory signs in 92.8% and clinical recurrences of life-threatening events in 71.4% but they were induced during programmed electrical stimulation only in 4 of 18 patients. Atrial fibrillation was the most frequent coexistent arrhythmia (19%). In summary, there are frequent premonitory signs (particularly atrial fibrillation), and also malignant arrhythmic recurrences but a poor inducibility at the electrophysiology laboratory. It is very difficult to stratify the risk because of the low predictive value of diagnostic methods.
Asunto(s)
Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Masculino , Arritmias Cardíacas/complicaciones , Muerte Súbita Cardíaca/etiología , Paro Cardíaco/etiología , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/tratamiento farmacológico , Cuba/epidemiología , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables , Electrocardiografía , Técnicas Electrofisiológicas Cardíacas , Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Factores de RiesgoRESUMEN
The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , LDL-Colesterol/sangre , Ácidos Heptanoicos/uso terapéutico , Pirroles/uso terapéutico , Adulto , Anciano , Anticolesterolemiantes/administración & dosificación , Atorvastatina , Enfermedad Coronaria/mortalidad , Método Doble Ciego , Femenino , Estudios de Seguimiento , Paro Cardíaco/epidemiología , Ácidos Heptanoicos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/epidemiología , Pirroles/administración & dosificación , Accidente Cerebrovascular/epidemiología , Factores de TiempoRESUMEN
Sudden cardiac death due to electrical causes in individuals with no evidence of structural heart disease is an important clinical and public health problem, and it is not yet solved. The objectives of this study were: to characterize patients reanimated from a sudden death event of electrical cause; to know the mediated evolution during a period of three years and to study premonitory electrical signs. 42 individuals were studied, 30 were male and 12 female, mean age 37.7 years, healthy heart, by clinic and paraclinic methods. Nine subpopulations were studied, being Brugada syndrome, long QT syndrome and idiopathic ventricular fibrillation the most frequent. Ventricular fibrillation and twisting of the points were the arrhythmias responsible for most death events. There were premonitory signs in 92.8% and clinical recurrences of life-threatening events in 71.4% but they were induced during programmed electrical stimulation only in 4 of 18 patients. Atrial fibrillation was the most frequent coexistent arrhythmia (19%). In summary, there are frequent premonitory signs (particularly atrial fibrillation), and also malignant arrhythmic recurrences but a poor inducibility at the electrophysiology laboratory. It is very difficult to stratify the risk because of the low predictive value of diagnostic methods.
Asunto(s)
Arritmias Cardíacas/complicaciones , Muerte Súbita Cardíaca/etiología , Paro Cardíaco/etiología , Adolescente , Adulto , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/tratamiento farmacológico , Niño , Preescolar , Cuba/epidemiología , Muerte Súbita Cardíaca/epidemiología , Muerte Súbita Cardíaca/prevención & control , Desfibriladores Implantables/estadística & datos numéricos , Electrocardiografía , Técnicas Electrofisiológicas Cardíacas , Femenino , Paro Cardíaco/epidemiología , Paro Cardíaco/terapia , Humanos , Masculino , Factores de RiesgoAsunto(s)
Reanimación Cardiopulmonar/tendencias , Cardioversión Eléctrica/tendencias , Paro Cardíaco/terapia , Fibrilación Ventricular/historia , Cardiografía de Impedancia/historia , Cardiografía de Impedancia/tendencias , Reanimación Cardiopulmonar/historia , Reanimación Cardiopulmonar/métodos , Cardioversión Eléctrica/historia , Electrocardiografía/historia , Electrocardiografía/tendencias , Femenino , Paro Cardíaco/diagnóstico , Paro Cardíaco/epidemiología , Historia del Siglo XVIII , Historia del Siglo XIX , Historia del Siglo XX , Historia Antigua , Humanos , Masculino , Irlanda del Norte/epidemiología , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/terapiaRESUMEN
BACKGROUND: The relation of trans-fatty acid intake to life-threatening arrhythmias and primary cardiac arrest is unknown. METHODS AND RESULTS: We investigated the association of trans-fatty acid intake, assessed through a biomarker, with the risk of primary cardiac arrest in a population-based case-control study. Cases, aged 25 to 74 years, were out-of-hospital cardiac arrest patients attended by paramedics in Seattle, Washington from 1988 to 1999 (n=179). Controls, matched to cases by age and sex, were randomly identified from the community (n=285). Participants were free of previous clinically diagnosed heart disease. Blood was obtained at the time of cardiac arrest (cases) or at the time of an interview (controls) to assess trans-fatty acid intake. Higher total trans-fatty acids in red blood cell membranes was associated with a modest increase in the risk of primary cardiac arrest after adjustment for medical and lifestyle risk factors (odds ratio for interquintile range, 1.5; 95% CI, 1.0 to 2.1). However, trans isomers of oleic acid were not associated with risk (odds ratio for interquintile range, 0.8; 95% CI, 0.5 to 1.2), whereas higher levels of trans isomers of linoleic acid were associated with 3-fold increase in risk (odds ratio for interquintile range, 3.1; 95% CI, 1.7 to 5.4). CONCLUSIONS: These findings suggest that dietary intake of total trans-fatty acids is associated with modest increase and trans isomers of linoleic acid with a larger increase in the risk of primary cardiac arrest. These associations need to be confirmed in future studies that distinguish between trans isomers of linoleic acid and trans isomers of oleic acid.
Asunto(s)
Membrana Celular/metabolismo , Ácidos Grasos Insaturados/metabolismo , Paro Cardíaco/epidemiología , Paro Cardíaco/metabolismo , Adulto , Distribución por Edad , Anciano , Estudios de Casos y Controles , Grasas Insaturadas en la Dieta/metabolismo , Eritrocitos/química , Eritrocitos/metabolismo , Ácidos Grasos Insaturados/análisis , Femenino , Humanos , Ácido Linoleico/análisis , Ácido Linoleico/metabolismo , Masculino , Persona de Mediana Edad , Conformación Molecular , Oportunidad Relativa , Ácido Oléico/análisis , Ácido Oléico/metabolismo , Medición de Riesgo , Factores de Riesgo , Distribución por Sexo , Estereoisomerismo , Washingtón/epidemiologíaRESUMEN
High circulating total homocysteine (tHcy) concentration, which is influenced by folate and vitamin B-12 status, is a suspected cause of cardiovascular events. This relation has been investigated in both case-control and prospective studies but has not been evaluated for different sex x age subgroups of the general U.S. population. We used data on adult (i.e., aged > or =40 y) male (n = 1097) and female (n = 1107) participants in the third National Health and Nutrition Examination Survey, excluding diabetics and those supplemented with estrogen, vitamins or minerals, to evaluate the association between serum tHcy concentration and self-report of heart attack or stroke. After adjustment for age, race-ethnicity, smoking, blood pressure, blood pressure medication, body mass index and serum concentrations of creatinine and cholesterol, past events were reported 2.4 (95% confidence interval 1.0-5.5) times as often by men with tHcy concentration of >12 micromol/L as by men with lower values. The odds ratio for women was 2.6 (95% confidence interval 1.1-6.6) after adjustment for the same factors plus menopausal status. A stronger relation in men aged < or =60 y compared with older men may help reconcile conflicting results of earlier studies.
Asunto(s)
Paro Cardíaco/etiología , Homocisteína/sangre , Hiperhomocisteinemia/complicaciones , Autorrevelación , Accidente Cerebrovascular/etiología , Adulto , Factores de Edad , Anciano , Femenino , Ácido Fólico/sangre , Paro Cardíaco/sangre , Paro Cardíaco/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Encuestas Nutricionales , Factores de Riesgo , Factores Sexuales , Accidente Cerebrovascular/sangre , Accidente Cerebrovascular/epidemiología , Vitamina B 12/sangreRESUMEN
Whether the dietary intake of long-chain n-3 polyunsaturated fatty acids (PUFAs) from seafood reduces the risk of ischemic heart disease remains a source of controversy, in part because studies have yielded inconsistent findings. Results from experimental studies in animals suggest that recent dietary intake of long-chain n-3 PUFAs, compared with saturated and monounsaturated fats, reduces vulnerability to ventricular fibrillation, a life-threatening cardiac arrhythmia that is a major cause of ischemic heart disease mortality. Until recently, whether a similar effect of long-chain n-3 PUFAs from seafood occurred in humans was unknown. We summarize the findings from a population-based case-control study that showed that the dietary intake of long-chain n-3 PUFAs from seafood, measured both directly with a questionnaire and indirectly with a biomarker, is associated with a reduced risk of primary cardiac arrest in humans. The findings also suggest that 1) compared with no seafood intake, modest dietary intake of long-chain n-3 PUFAs from seafood (equivalent to 1 fatty fish meal/wk) is associated with a reduction in the risk of primary cardiac arrest; 2) compared with modest intake, higher intakes of these fatty acids are not associated with a further reduction in such risk; and 3) the reduced risk of primary cardiac arrest may be mediated, at least in part, by the effect of dietary n-3 PUFA intake on cell membrane fatty acid composition. These findings also may help to explain the apparent inconsistencies in earlier studies of long-chain n-3 PUFA intake and ischemic heart disease.
Asunto(s)
Ácidos Grasos Omega-3/administración & dosificación , Paro Cardíaco/dietoterapia , Adulto , Anciano , Estudios de Casos y Controles , Ingestión de Alimentos , Membrana Eritrocítica/química , Ácidos Grasos Omega-3/análisis , Femenino , Paro Cardíaco/epidemiología , Paro Cardíaco/prevención & control , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Alimentos Marinos , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To assess whether the dietary intake of long-chain n-3 polyunsaturated fatty acids from seafood, assessed both directly and indirectly through a biomarker, is associated with a reduced risk of primary cardiac arrest. DESIGN: Population-based case-control study. SETTING: Seattle and suburban King County, Washington. PARTICIPANTS: A total of 334 case patients with primary cardiac arrest, aged 25 to 74 years, attended by paramedics during 1988 to 1994 and 493 population-based control cases and controls, matched for age and sex, randomly identified from the community. All cases and controls were free of prior clinical heart disease, major comorbidity, and use of fish oil supplements. MEASURES OF EXPOSURE: Spouses of case patients and control subjects were interviewed to quantify dietary n-3 polyunsaturated fatty acid intake from seafood during the prior month and other clinical characteristics. Blood specimens from 82 cases (collected in the field) and 108 controls were analyzed to determine red blood cell membrane fatty acid composition, a biomarker of dietary n-3 polyunsaturated fatty acid intake. RESULTS: Compared with no dietary intake of eicosapentaenoic acid (C20:5n-3) and docosahexaenoic acid (C22:6n-3), an intake of 5.5 g of n-3 fatty acids per month (the mean of the third quartile and the equivalent of one fatty fish meal per week) was associated with a 50% reduction in the risk of primary cardiac arrest (odds ratio [OR], 0.5; 95% confidence interval [CI], 0.4 to 0.8), after adjustment for potential confounding factors. Compared with a red blood cell membrane n-3 polyunsaturated fatty acid level of 3.3% of total fatty acids (the mean of the lowest quartile), a red blood cell n-3 polyunsaturated fatty acid level of 5.0% of total fatty acids (the mean of the third quartile) was associated with a 70% reduction in the risk of primary cardiac arrest (OR, 0.3; 95% CI, 0.2 to 0.6). CONCLUSION: Dietary intake of n-3 polyunsaturated fatty acids from seafood is associated with a reduced risk of primary cardiac arrest.